Equities

Deepverge PLC

Deepverge PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.25
  • Today's Change0.75 / 7.89%
  • Shares traded1.35m
  • 1 Year change-68.46%
  • Beta1.7871
Data delayed at least 20 minutes, as of Jun 30 2022 16:29 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Deepverge PLC is an Ireland-based vertically integrated pharmaceutical company. The Company provides core skin and human testing technology. Its is engaged in collaborating technology platforms with partners in artificial intelligence, clinical research, water technologies, medical device and life science. Its collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple partner technologies.

  • Revenue in GBP (TTM)9.30m
  • Net income in GBP-2.68m
  • Incorporated2016
  • Employees73.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DVRG:LSE since
announced
Transaction
value
Glanaco LtdDeal completed17 Mar 202217 Mar 2022Deal completed-19.61%1.42m
Data delayed at least 20 minutes, as of Jun 30 2022 16:29 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ValiRx Plc0.00-1.52m10.57m7.00--2.94-----0.0234-0.02340.000.05530.00----0.00-36.57-58.96-35.94-77.90-----------605.720.0169-------5.19------
Aquila Services Group PLC10.12m579.00k11.19m76.0019.861.8216.051.110.01410.01410.24590.15371.21--4.16--6.955.219.336.9821.8022.985.724.49----0.044266.5632.4111.29209.637.45-4.91-4.11
React Group PLC7.70m389.00k11.28m28.0015.811.9617.281.470.00070.00070.01360.00551.64--4.83--8.29-13.5213.61-19.1730.7629.505.05-9.141.00--0.0356--76.6325.93106.91---19.50--
Bivictrix Therapeutics PLC0.00-2.34m13.22m5.00--2.09-----0.1694-0.16940.000.09570.00----0.00-58.88---64.64-------------2.340.0374-------450.59------
Afriag Global PLC0.00-2.16m13.47m18.00--0.8236-----0.0665-0.06650.000.02190.00-------82.61-21.17-126.34-30.96--7.04---25.49---7.120.00---100.00---586.16------
All Things Considered Group PLC9.14m-2.35m14.57m17.00--7.09--1.59-0.2456-0.24560.9540.21441.24--4.50---44.76---127.65--9.25---36.18------0.4929--28.78---706.56------
Silver Bullet Data Services Group Ltd3.81m-8.51m15.03m62.00--1.38--3.94-0.6342-0.63420.28390.6878----------------73.11---223.42-----406.120.017--36.58---66.28------
NAHL Group PLC38.95m156.00k15.10m259.0096.740.26672.860.38780.00340.00340.84221.220.3915--1.59150,374.503.635.674.627.0845.1848.169.2611.87--8.840.26293.43-4.72-4.64169.33-58.20-0.1605--
One Media IP Group PLC4.39m544.58k15.24m11.0030.181.0312.763.470.00230.00230.01640.06640.2548--3.35399,052.703.164.403.364.7774.9155.5312.4113.60--4.590.1058--9.5916.50-13.5954.0079.06-4.98
ReNeuron Group Plc274.00k-9.49m15.84m43.00--1.12--57.79-0.1854-0.18540.00540.24860.0149--0.40536,372.09-51.51-34.68-86.63-40.80-----3,463.14-1,088.16---68.980.0429---95.7654.710.5696---38.88--
ImmuPharma PLC118.35k-8.17m16.10m14.00--3.65--136.05-0.0325-0.03250.00050.01550.014--0.40178,453.57-96.66-94.13-116.20-109.64-----6,906.55-6,235.41---2.190.0002---6.57-6.40-19.15--60.85--
Gattaca PLC411.39m-701.00k17.28m540.00--0.5517.630.042-0.0219-0.078212.710.9714.61--8.09851,741.20-0.7856-2.23-1.81-4.2810.3510.76-0.1704-0.5376--3.200.3055---22.25-7.61146.08-29.0018.76-42.07
Deepverge PLC9.30m-2.68m20.87m73.00--0.860238.872.25-0.0148-0.01480.04720.11040.33462.612.26127,356.20-9.64-26.64-11.58-35.4057.1253.12-28.82-96.032.21-8.000.0876--107.38182.081.43--25.29--
National Milk Records Plc22.58m2.36m21.13m276.008.952.956.530.9360.11120.11121.060.33751.7822.886.1381,804.3518.65--27.74--42.79--10.46--1.41--0.2209--1.51--102.78------
Skillcast Group PLC8.41m377.63k21.47m86.0052.062.9732.512.550.00460.00460.10360.0807------97,768.14--------70.54--4.49-----35.610.0818--15.29---58.23------
DSW Capital PLC2.69m1.38m25.03m9.0018.119.2117.279.310.06430.06430.12570.1264------298,777.80------------51.17------0.3353--39.37--59.44------
Data as of Jun 30 2022. Currency figures normalised to Deepverge PLC's reporting currency: UK Pound GBX

Institutional shareholders

4.05%Per cent of shares held by top holders
HolderShares% Held
ISPartners Investment Solutions AGas of 13 Apr 20228.70m3.96%
Trium Capital LLPas of 28 Sep 2020200.00k0.09%
Data from 29 Oct 2021 - 01 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.